Legal & General Group
ROIV icon

Legal & General Group’s Roivant Sciences ROIV Stock Holding History

Legal & General Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.5M Buy
721,552
+160,245
+29% +$4.74M 0.01% 784
2026
Q1 		$15.5M Sell
561,307
-28,366
-5% -$729K ﹤0.01% 925
2025
Q4 		$12.8M Buy
589,673
+40,344
+7% +$796K ﹤0.01% 1036
2025
Q3 		$8.31M Sell
549,329
-61,827
-10% -$765K ﹤0.01% 1309
2025
Q2 		$6.89M Sell
611,156
-3,274
-0.5% -$35.5K ﹤0.01% 1385
2025
Q1 		$6.2M Buy
614,430
+11,572
+2% +$125K ﹤0.01% 1416
2024
Q4 		$7.13M Sell
602,858
-2,730
-0.5% -$32.3K ﹤0.01% 1379
2024
Q3 		$6.99M Buy
605,588
+72,298
+14% +$823K ﹤0.01% 1393
2024
Q2 		$5.64M Buy
533,290
+98,950
+23% +$1.08M ﹤0.01% 1458
2024
Q1 		$4.58M Buy
434,340
+140,375
+48% +$1.51M ﹤0.01% 1565
2023
Q4 		$3.3M Sell
293,965
-1,158
-0.4% -$11.3K ﹤0.01% 1714
2023
Q3 		$3.45M Sell
295,123
-31,961
-10% -$361K ﹤0.01% 1643
2023
Q2 		$3.3M Buy
327,084
+210,001
+179% +$1.88M ﹤0.01% 1689
2023
Q1 		$864K Buy
117,083
+15,588
+15% +$128K ﹤0.01% 2185
2022
Q4 		$811K Buy
101,495
+3,578
+4% +$19.9K ﹤0.01% 2211
2022
Q3 		$315K Buy
+97,917
New +$379K ﹤0.01% 2465

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Legal & General Group's ROIV Position: Q2 2026 in Review

Legal & General Group increased its Roivant Sciences (ROIV) stake by 29% in Q2 2026, buying an estimated $4.74M and bringing the position to 721,552 shares worth $25.5M. The position accounts for 0.01% of the portfolio, ranked #784.

Legal & General Group first reported a position in ROIV in Q3 2022 and has held it in 16 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Legal & General Group held 721,552 shares of Roivant Sciences worth $25.5M as of Q2 2026.
  • Legal & General Group bought 160,245 Roivant Sciences shares in Q2 2026, an estimated $4.74M.
  • Roivant Sciences made up 0.01% of Legal & General Group's portfolio in Q2 2026, its #784 holding.
  • Legal & General Group first reported a position in Roivant Sciences in Q3 2022 and has held it in 16 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.